PA8502901A1 - Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1 - Google Patents

Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1

Info

Publication number
PA8502901A1
PA8502901A1 PA20008502901A PA8502901A PA8502901A1 PA 8502901 A1 PA8502901 A1 PA 8502901A1 PA 20008502901 A PA20008502901 A PA 20008502901A PA 8502901 A PA8502901 A PA 8502901A PA 8502901 A1 PA8502901 A1 PA 8502901A1
Authority
PA
Panama
Prior art keywords
release
combination
processing
inhibit
compounds
Prior art date
Application number
PA20008502901A
Other languages
English (en)
Inventor
Bruce Henry Littman
Thasia Louise Goodwin Woodworth
Mark Anthony Dombroski
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8502901A1 publication Critical patent/PA8502901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EL INVENTO SE REFIERE A METODOS Y COMPOSICIONES PARA TRATAR Y PREVENIR ESTADOS MORBOSOS MEDIADOS POR LA INTERLEUQUINA 1 (Il-1). EN LOS METODOS Y LAS COMPOSICIONES SE USA UN POLIPÉPTIDO ANTAGONISTA DEL RECEPTOR DE LA INTERLEUQUINA 1 (Il-1ra), O UNA VARIANTE DEL MISMO, EN COMBINACION CON UN AGENTE NO ESTEROIDE QUE INHIBE EL PROCESAMIENTO Y LA LIBERACIÓN DE Il-1.
PA20008502901A 1999-09-14 2000-09-11 Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1 PA8502901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
PA8502901A1 true PA8502901A1 (es) 2002-02-21

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008502901A PA8502901A1 (es) 1999-09-14 2000-09-11 Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1

Country Status (13)

Country Link
EP (1) EP1214087A1 (es)
JP (1) JP2003509378A (es)
AR (1) AR033650A1 (es)
AU (1) AU6464400A (es)
BR (1) BR0014003A (es)
CA (1) CA2383026A1 (es)
CO (1) CO5190701A1 (es)
EC (1) ECSP003652A (es)
GT (1) GT200000155A (es)
PA (1) PA8502901A1 (es)
PE (1) PE20010685A1 (es)
TN (1) TNSN00183A1 (es)
WO (1) WO2001019390A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10765747B2 (en) 2004-04-02 2020-09-08 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
WO2008129288A2 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
PE20221627A1 (es) 2015-02-16 2022-10-19 Univ Queensland Sulfonilureas y compuestos relacionados y uso de estos
US11858922B2 (en) 2016-02-16 2024-01-02 The University Of Queensland Sulfonylureas and related compounds and use of same
ES2927777T3 (es) * 2016-04-18 2022-11-10 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
WO2018136890A1 (en) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Chemical compounds as inhibitors of interleukin-1 activity
AU2017416068A1 (en) 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
EP3978489A1 (en) 2017-07-07 2022-04-06 Inflazome Limited Novel sulfonamide carboxamide compounds
MX2020000911A (es) 2017-07-24 2020-09-10 Novartis Ag Star Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
AU2018317798A1 (en) * 2017-08-15 2020-02-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
WO2019034696A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
EP3668842A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
CA3078195A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
EP3817817A1 (en) 2018-07-03 2021-05-12 Novartis AG Nlrp modulators
EP3823726A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche SA Sulfonylurea compounds as inhibitors of interleukin-1 activity
JP2022505525A (ja) * 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
EP3911631A4 (en) 2019-01-14 2022-09-28 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
EP4157860A4 (en) * 2020-05-25 2024-03-06 Beijing Vdjbio Co., Ltd. INTERLEUKIN-1 RECEPTOR ANTAGONIST AND FUSION PROTEIN WITH IT

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
CN1127479C (zh) * 1997-01-29 2003-11-12 辉瑞大药厂 磺酰脲衍生物及其在白介素－1活性的控制中的用途
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins

Also Published As

Publication number Publication date
BR0014003A (pt) 2002-05-21
EP1214087A1 (en) 2002-06-19
AU6464400A (en) 2001-04-17
AR033650A1 (es) 2004-01-07
PE20010685A1 (es) 2001-07-03
WO2001019390A1 (en) 2001-03-22
GT200000155A (es) 2002-03-08
JP2003509378A (ja) 2003-03-11
CA2383026A1 (en) 2001-03-22
ECSP003652A (es) 2002-04-23
TNSN00183A1 (fr) 2005-11-10
CO5190701A1 (es) 2002-08-29

Similar Documents

Publication Publication Date Title
PA8502901A1 (es) Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
UY26296A1 (es) Tratamiento medicamentoso del síndrome de piernas inquietas
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
ES2188177T3 (es) Composicion para la prevencion y/o el tratamiento de la osteoporosis y las alteraciones debidas al sindrome menopausico, que comprende propionil-l-carnitina y genisteina.
CO5160262A1 (es) Formulaciones farmaceuticas de liberacion controlada
BR9612661A (pt) Utilização de uma combinaç i de tensoatives agentes quelantes e óleos essenciais para desinfecção eficaz
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
AR028512A1 (es) Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
AR031473A1 (es) Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
AR109263A2 (es) Composición que comprende moxidectina
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
ATE333896T1 (de) Vaskularisierungsinhibitoren
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
AR028730A1 (es) Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxis de la obesidad y utilizacion de dichos compuestos
PE20010642A1 (es) Combinacion de pramipexol y clonidina para el tratamiento del sindrome de piernas inquietas
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
UY28007A1 (es) Tratamiento terapeutico
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
AR047480A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion